Aquestive Therapeutics (AQST) Gains from Sales and Divestitures (2018 - 2020)

Aquestive Therapeutics' Gains from Sales and Divestitures history runs 3 years deep, the most recent figure standing at $64000.0 for Q4 2020.

• In Q4 2020, Gains from Sales and Divestitures fell 48.8% year-over-year to $64000.0; the TTM figure through Dec 2020 stood at $64000.0 (down 48.8% YoY), while the FY2020 annual figure was $64000.0, down 48.8% from the prior year.
• Gains from Sales and Divestitures was $64000.0 for Q4 2020 at Aquestive Therapeutics, roughly flat from $64000.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $125000.0 in Q4 2019 to a low of $29802.0 in Q3 2018.
• Historically, Gains from Sales and Divestitures has averaged $61680.2 across 3 years, with a median of $60000.0 in 2018.
• The sharpest annual moves came in 2019 and 2020: Gains from Sales and Divestitures surged 218.77% in 2019, then sank 48.8% in 2020.
• A 3-year view of Gains from Sales and Divestitures shows it stood at $60000.0 in 2018, then surged by 108.33% to $125000.0 in 2019, then tumbled by 48.8% to $64000.0 in 2020.
• The last three Gains from Sales and Divestitures figures came in at $64000.0 (Q4 2020), $64000.0 (Q3 2020), and $60000.0 (Q2 2020), per Business Quant data.